CLSDQ · Clearside Biomedical, Inc. · Financials
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date the financial statements are issued. Based on our current plans and forecasted expenses and our cash and cash equivalents, we do not believe we will be able to fund our operations for the next 12 months from the date of this filing.”View the 10-Q filed Nov 14, 2025
Market Cap
$1.30M
Shares
5.23M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$1.66M
-79.8%
FY2024
Net Income
-$34.35M
-5.7%
FY2024
Gross Margin
91.05%
-4.6pp
FY2024
Operating Margin
-1735.7%
-1433.7pp
FY2024
Diluted EPS
-$0.47
+11.3%
FY2024
Operating Cash Flow
-$24.7M
-36.2%
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.33M | $1.66M | $8.23M | $1.33M | $29.58M | $7.89M | $2.17M | $30K | $345K | $520K | — | — | |
| $397K | $149K | $355K | $204K | $0 | — | — | — | — | — | — | — | |
| $2.93M | $1.52M | $7.87M | $1.12M | $29.58M | — | — | — | — | — | — | — | |
| — | 91.05% | 95.68% | 84.63% | 100% | — | — | — | — | — | — | — | |
| $13.22M | $18.59M | $20.85M | $19.63M | $18.54M | $15.07M | $15.66M | $68.29M | $49.05M | $19.46M | $10.76M | $6.69M | |
| $12.67M | $11.81M | $11.87M | $11.77M | $11.67M | $10.76M | $16.82M | $14.68M | $9.7M | $6.26M | $6.56M | $3.13M | |
| — | -$339K | $0 | $0 | — | — | — | — | — | — | — | — | |
| $33.9M | — | $33.07M | $31.6M | $30.2M | $25.83M | $32.48M | $82.98M | $58.75M | $25.72M | $17.32M | $9.82M | |
| -$22.96M | -$28.88M | -$24.84M | -$30.28M | -$627K | -$17.94M | -$30.3M | -$82.95M | -$58.41M | -$25.2M | -$17.32M | -$9.82M | |
| — | -1735.7% | -302.02% | -2281.61% | -2.12% | -227.2% | -1394.57% | -276483.33% | -16929.86% | -4845.77% | — | — | |
| — | -$29.22M | -$24.84M | -$30.28M | — | — | — | — | — | — | — | — | |
| $700K | $1.46M | $1.72M | $669K | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | -$275K | -$466K | $127K | -$567K | -$684K | -$322K | -$366K | |
| -$26M | -$34.35M | -$32.49M | -$32.95M | $376K | -$18.21M | -$30.77M | -$82.82M | -$58.98M | -$25.88M | -$17.64M | -$10.19M | |
| — | -2064.42% | -394.91% | -2482.82% | 1.27% | -230.68% | -1416.01% | -276060% | -17094.2% | -4977.31% | — | — | |
| — | — | — | — | — | — | -$30.77M | -$82.82M | -$58.97M | -$25.9M | -$17.64M | -$10.19M | |
| USD/shares | $0.03 | -$0.47 | -$0.53 | -$0.55 | $0.01 | -$0.39 | -$0.81 | — | — | — | — | — |
| USD/shares | $0.03 | -$0.47 | -$0.53 | -$0.55 | $0.01 | -$0.39 | -$0.81 | — | — | — | — | — |
| shares | — | 73.8M | 61.81M | 60.2M | 58.49M | 46.51M | 38.17M | 30.73M | 25.31M | 13.11M | 2.34M | 1.74M |
| shares | — | 73.8M | 61.81M | 60.2M | 59.91M | 46.51M | 38.17M | 30.73M | 25.31M | 13.11M | 2.34M | 1.74M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| License | $1,700,000 | $8,200,000 | $1,300,000 | $29,600,000 | $7,700,000 | — |
| Training Materials and Clinical Supplies | $900,000 | $1,200,000 | $1,200,000 | — | — | — |
| Product And Service Other | $700,000 | $600,000 | $100,000 | — | — | — |
| Other Agreement | — | $50,000 | $13,000 | $200,000 | $105,000 | $105,000 |